I wish Acadia would get their A into G and start the ball rolling to offer NNZ2591 to Retts and Fragile-X sufferers. Perhaps they are waiting for more success with Neurens current trials for NNZ2591, but surely it makes sense being the "superior" drug with little or no side-effects.... watch this space... Daybue II is coming.
I wish Acadia would get their A into G and start the ball...
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.58 |
Change
-0.030(0.19%) |
Mkt cap ! $1.956B | |||
| Open | High | Low | Value | Volume |
| $15.83 | $15.87 | $15.20 | $6.400M | 414.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 35 | $15.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.59 | 228 | 5 |
View Market Depth
| Last trade - 15.56pm 16/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |